Pharma News

New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.

Johnson & Johnson announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) that is refractory to systemic therapies.1,2 The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive Disease Week (DDW) 2026.

In-Cosmetics Global 2026 Exhibition & Conference was held in Paris, France at the Paris Expo porte de versailles from 14th to 16th April 2026.

In a major development in the fight against obesity, Boehringer Ingelheim has announced encouraging results for its experimental drug survodutide, offering new hope for people struggling with overweight and obesity.

Boehringer Ingelheim India Private Limited and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur today signed a Memorandum of Understanding (MoU) to advance pharmaceutical research, education and innovation. The five-year collaboration will create new pathways for researchers and students in Bihar and the wider region to engage with global-standard open science platforms, joint research initiatives and capability-building programmes thus strengthening the talent pipeline for India’s next phase of pharmaceutical innovation.

Colorectal cancer is one of the most common types of cancer in the Western world and a leading cause of cancer-related deaths. Age, diet and lifestyle are known risk factors. However, in most cases we still lack a precise understanding of what triggers the disease.

In recent years, researchers have increasingly turned their attention to the ecosystem of the gut – the vast community of bacteria, viruses and other microorganisms that live there.

Hygiene in everyday items that touch the body—such as clothing, masks, and toothbrushes—is critically important. The underlying principle of how graphene selectively eliminates only bacteria has now been revealed. A KAIST research team has presented the potential for a next-generation antibacterial material that is safe for the human body and capable of replacing antibiotics.